Monday, August 14, 2023 Daily Archives

Emergent scaling back CDMO biz, reducing ops in MD and MA

by

Emergent BioSolutions will reduce operations at the troubled Bayview facility in Baltimore, Maryland among plans to step away from its CDMO business. For the second quarter 2023, Emergent recorded sales of $338 million, up 39% on the same period last year. This included $29 million in revenues received from Emergent’s role as a contract development and manufacturing organization (CDMO), a sector the firm says it has begun reducing investment in and de-emphasizing focus on. “Our decision to deemphasize growth in CDMO…

August 14, 2023

Astellas in $50m allogeneic CAR-T deal with Poseida

by

Astellas receives the rights to negotiation and first refusal for allogeneic CAR-T cell therapy, P-MUC1C-ALLO1, as it takes an 8.8% stake in Poseida Therapeutics. Astellas Pharma will invest $25 million to own 8.8% of common stock of cell and gene therapy (CGT) firm Poseida Therapeutics. Additionally, Astellas will make a one-time payment of an additional $25 million to gain the rights of exclusive negotiation and first refusal to license chimeric antigen receptor (CAR) T-cell therapy P-MUC1C-ALLO1, which is in Phase I…

August 14, 2023

Webcast: How to cultivate a sustainable talent ecosystem

by

With talent supply chain shortages continuing to be a top concern across the life sciences industry, we ask Lead Candidate CEO Andrew Mears what can be done? Talent issues are plaguing both the biopharma industry and the contract manufacturing sector that services it. Continually, the need for increasingly complex and specific skill sets, the dwindling talent pool, and the difficulties of retaining staff are affecting biopharma resilience and threatening both current supply chains and future R&D. So how big are…

August 14, 2023

Cytomos bags $5m to advance cell analysis platform

by

Edinburgh-based life science firm Cytomos has secured $5 million in funding to scale-up market-testing of its platform Cytomos Dielectric Spectroscopy (CDS). The firm has developed its CDS platform to meet the unmet requirements of the biopharma industry. Cytomos said the platform is high-speed, scalable, and cheaper than other cell analysis systems available in the market. “Whilst traditional cell analysis only considers reactive parameters within the cell culture media (e.g., metabolites [glucose/lactate], DO, pH) predominantly offline to interpret with 1-2 days…

August 14, 2023